中国药厂成功“仿制”瑞德西韦目前正在量产中光华日报

12399456https://www.upal.com.my/zh/feeds/jobFeedKwongwahArray ( [0] => HTTP/1.1 200 OK [1] => Date: Sat, 24 May 2025 19:43:56 GMT [2] => Content-Type: text/xml; charset=utf-8 [3] => Connection: close [4] => Nel: {"success_fraction":0,"report_to":"cf-nel","max_age":604800} [5] => Report-To: {"endpoints":[{"url":"https:\/\/a.nel.cloudflare.com\/report\/v4?s=kWmciIM8Q1X%2FxEmTWA3ZJlPdpaBF%2Ft3h4DCPQvVbpRiF3GijyrXnwVr3VrKkrWthyWgqeeV8gle22z3lRlKC%2FuP2G7ovkdseuxpg%2BnkSfeVgkgrLSek6iTDkfg9%2BaZyLQAM%3D"}],"group":"cf-nel","max_age":604800} [6] => Server: cloudflare [7] => Vary: Accept-Encoding [8] => X-Powered-By: PHP/7.4.33 [9] => Cache-Control: no-cache, private [10] => Cf-Ray: 944f48ebb9d997ba-KUL [11] => X-Frame-Options: SAMEORIGIN [12] => X-Xss-Protection: 1; mode=block [13] => X-Content-Type-Options: nosniff [14] => Referrer-Policy: no-referrer-when-downgrade [15] => Cf-Cache-Status: DYNAMIC [16] => Set-Cookie: UpalLiveSession=eyJpdiI6IitCZ2JvNWRQVzJ2ZWpnXC8xMkplTWRnPT0iLCJ2YWx1ZSI6IjExaFQrTnNoUWlYVFlzK3JOMXdtYTNEYXdwVXlHQlpkclU4bWJjVU9ieGNiVDZITmVKNStteWRvVk9aMDhnK2xOOVk1MkZhTklqQ2Z5UVNKM2ZIajJBPT0iLCJtYWMiOiI1Mjk4NzUxMDc3MjdhMDIzY2I1MDI5YWE2ZmM1YTQxMDZhNWJiYTVlNTJjZWQ0NGE0ZjZlMGM1OWRmOGJkNWY1In0%3D; HttpOnly; Path=/; Max-Age=94608000; Expires=Tue, 23 May 2028 19:43:23 GMT [17] => alt-svc: h3=":443"; ma=86400 [18] => server-timing: cfL4;desc="?proto=TCP&rtt=1103&min_rtt=874&rtt_var=640&sent=4&recv=7&lost=0&retrans=0&sent_bytes=3000&recv_bytes=756&delivery_rate=3253932&cwnd=252&unsent_bytes=0&cid=b903c38ec5eb4c07&ts=22&x=0" ) 789

在中国武汉爆发新冠肺炎疫情持续延烧，周二由美国药厂吉利德科学公司研发的实验药品“瑞德西韦（Remdesivir）”有望成为抑制新冠肺炎的药物，却爆出被中国抢先注册专利的消息。更有甚者，中国药厂“博瑞生物医药”于周三公布，它们已成功仿制出该药品的“原料药合成工艺技术和制剂技术”，目前正在量产瑞德西韦制剂。